NCT07211776View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

99

Participants

Timeline

Start Date

December 27, 2025

Primary Completion Date

March 14, 2027

Study Completion Date

January 29, 2028

Conditions

Thyroid Eye Disease (TED)

Interventions

DRUG

ZL-1109 (VRDN-003)

ZL-1109 subcutaneous injection

DRUG

Placebo

Matching placebo subcutaneous injection

Trial Locations (27)

Unknown

Site01006, Beijing

Site01009, Beijing

Site01010, Beijing

Site01029, Bengbu

Site01020, Changsha

Site01022, Chengdu

Site01031, Chongqing

Site01011, Dalian

Site01008, Foshan

Site01004, Fuzhou

Site01007, Guangzhou

Site01027, Guiyang

Site01018, Hangzhou

Site01002, Hefei

Site01024, Jinan

Site01005, Luoyang

Site01017, Nanchang

Site01001, Shanghai

Site01012, Shenyang

Site01023, Taiyuan

Site01013, Tianjin

Site01016, Wuxi

Site01028, Xi'an

Site01025, Xuzhou

Site01026, Yangzhou

Site01019, Zhengzhou

Site01030, Zhengzhou

All Listed Sponsors

lead

Zai Lab (Shanghai) Co., Ltd.

INDUSTRY